Live
- Stokes motivates his team to put in extra effort, says England pacer Potts
- From overcoming setbacks to leading India in U19 Women’s Asia Cup, Niki Prasad's amazing journey
- Constitution debate: PM Modi hails 'Nari Shakti'; makes strong pitch for 'United Bharat’
- Bihar: Inquiry initiated against principal who went to buy veggies during school hours
- TN: DMK postpones executive meet due to heavy rains & Parliament session
- Porous silicon oxide electrodes can fix durability issues in batteries: Researchers
- Jalandhar civic polls: AAP promises launch of 100 e-buses, round the clock water supply
- Economic upliftment of rural women is priority of Tripura govt: CM Saha
- Rajmata Jijabai Trophy: Manipur move to top of the table, T.N register first win
- Italian envoy Baroli hoping to strengthen ties with India through football
Lee Pharma to launch bio-cartilage tablets in UAE
Hyderabad: City-based pharmaceutical company, Lee Pharma on Friday said it has received marketing authorisation to market Bio-Cartilage...
Hyderabad: City-based pharmaceutical company, Lee Pharma on Friday said it has received marketing authorisation to market Bio-Cartilage Smoothwalktablets in United Arab Emirates region. This tablet is the first product in the nutraceutical segment from India to get approved in UAE.
Bio-Cartilage Smoothwalk tablets contain collagen type II, natural eggshell membrane, Boswellia and curcumin with vitamin D3 which mainly acts on joint and connective tissue disorders to increase cartilage in joints. The tablet is anovel composition of bio nutraceuticals with potent phyto nutrients to prevent joint and connective tissue disorders.
“Bio-Cartilage Smoothwalk tablets are already well accepted in India.It is being used in prevention therapy of knee surgery.The tabletgives relief for the patients who are suffering with painful and progressive arthritis,” Director of Lee Pharma, Alla Leela Rani said.
She further informed that the product is under registration in all Middle East, East Asian countries.The company is scheduled to file the dossier for marketing authorizationin the US in the thirdquarter of 2024.
